Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM Tweetorial
Safety of Quad Therapies
Pre-Survey

Please note - this is the pre-survey, you MUST complete the POST-survey to qualify for credit.
There is no fee to participate in this activity.

*1.What are your specialty & credentials?(Required.)

Hematologist

Medical Oncologist

Surgical Oncologist

Radiation Oncologist

Pathologist

Other MD/DO

Trainee/Fellow

Nurse

Pharmacist

Other (please specify)

2.What is your community of practice?

Academic

Community

Industry

Other (please specify)

*3.Recent meta-analyses have shown that adding anti-CD38 mAb to a triplet in NDMM leads to:(Required.)

Improved efficacy & higher rates of fatigue & GI AEs

Improved efficacy & higher rates of heme & infectious AEs

Increased efficacy & same rates of toxicity

No added benefit & same toxicity rates

*4.70 yo w/ NDMM (transplant ineligible) about to start Dara-VRd
Vaccine history: yearly flu & COVID, PPSV23 at 65
🚫no zoster or RSV vaccine

What’s the best plan?(Required.)

Nasal flu vaccine before cycle 1 D-VRd

RZV & RSV before cycle 1 D-VRd

Defer additional vaccinations until after induction

Acyclovir alone, skip RZV

*5.64yo w SR NDMM & well-controlled TDM starting induction
Per SWOG analysis (Banerjee 2025) how should Dara-VRd be adjusted?(Required.)

Change the dex dose to 80mg (to reduce the risk of Dara-IRR)

Reduce the dex dose to 20mg (to reduce the risk of PN &HG)

Switch daratumumab to isatuximab (to reduce the risk of Dara-IRR)

Switch bortezomib to carfilzomib (to reduce the risk of PN)

*6.This question is solely to establish a demographic profile of learners taking the pre-survey. This is not an application for CME credit. To take the post-survey and apply for CME credit, please use the links below.

*Please note that we will not forward or sell your contact information.*(Required.)

First Name *

Last Name *

Degree/Credentials:

Email Address (required to receive credit) *

Thank you for taking the pre-survey.

To view the activity, please visit > bonumce.com/ndmmtweetorial2
To take the post-survey and claim CME credit, please visit > _______________________________________

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Privacy & Cookie Notice

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM TweetorialSafety of Quad Therapies *Pre-Survey*

Four is More! Selecting and Optimizing Quadruplet Therapy in NDMM Tweetorial
Safety of Quad Therapies
Pre-Survey